# Jeremy Green
Jeremy Green is an American biotech investor who founded the healthcare-focused investment firm Redmile Group, LLC in 2007 and serves as its managing member.[1](https://hedgefunddb.com/Home/FundDetails/801-67747/REDMILE-GROUP-LLC) Before founding Redmile he ran Citigroup's European healthcare research team and co-founded the hedge fund Steeple Capital.[2](https://www.insidermonkey.com/hedge-fund/redmile-group/495/) His firm operates both as a hedge-fund complex and as venture-style biotech partnerships, and at its March 2024 filing reported $6.47 billion in discretionary assets.[1](https://hedgefunddb.com/Home/FundDetails/801-67747/REDMILE-GROUP-LLC) • [2](https://www.insidermonkey.com/hedge-fund/redmile-group/495/)
## Key facts
| Fact | Detail |
|---|---|
| Role | Managing member and principal owner of Redmile Group, LLC (50-75% ownership band, control person since 2007)[1](https://hedgefunddb.com/Home/FundDetails/801-67747/REDMILE-GROUP-LLC) • [3](https://privatefunddata.com/fund-employees/jeremy-charles-green-2810548/) |
| Prior career | Managing director, Citigroup European Healthcare Research; co-founder and director of research, Steeple Capital; analyst, Andor Capital[2](https://www.insidermonkey.com/hedge-fund/redmile-group/495/) |
| Firm scale | $6,473,965,022 discretionary assets across 27 clients (ADV, March 2024); $2.72B in 13F securities, Q1 2024[2](https://www.insidermonkey.com/hedge-fund/redmile-group/495/) |
| Fund raises | Redmile Biopharma Investments I $218.3M, II $675.4M, III $500.2M raised; RedCo II Master Fund $1,555.9M AUM[4](https://aum13f.com/person/jeremy-green) |
| Notable exits | Augmedix sold for $75.4M (Oct 2024); ADC Therapeutics partial sale $19.6M (Mar 2026); IGM Biosciences written off at $0 (Aug 2025)[5](https://www.secform4.com/insider-trading/1650527.htm) |
| Boards | Director or 10% owner roles at IGM Biosciences, Fate Therapeutics, Shattuck Labs, Absci; past director of 1Life Healthcare (One Medical)[5](https://www.secform4.com/insider-trading/1650527.htm) • [4](https://aum13f.com/person/jeremy-green) |
| Public service | Chairman, Prince's Trust America; Aspen Global Leadership Network member[6](https://lanterncare.com/members/jeremy-green/) |
## Career and education
Green built his career as a sell-side and buy-side healthcare analyst before becoming an investor. According to his firm profile, before relocating to the United States in 2004 he was a managing director at [Citigroup](https://www.edgepedia.org/citigroup), leading the European Healthcare Research Team covering medical technology, biotech, and healthcare services.[2](https://www.insidermonkey.com/hedge-fund/redmile-group/495/) In the US he co-founded Steeple Capital, where he was director of research, and worked as an analyst at Andor Capital.[2](https://www.insidermonkey.com/hedge-fund/redmile-group/495/)
In March 2007 he formed Redmile Group, LLC, a Delaware limited liability company, and became operational shortly thereafter; the firm's Form ADV states that Jeremy Green is the managing member and principal owner of the Firm.[1](https://hedgefunddb.com/Home/FundDetails/801-67747/REDMILE-GROUP-LLC) SEC-derived records list him as Jeremy Charles Green, Managing Member at Redmile Group, LLC in Larkspur, California, a control person since 2007 with a beneficial ownership band of 50-75 percent.[3](https://privatefunddata.com/fund-employees/jeremy-charles-green-2810548/)
## Redmile Group and Redmile Biopharma Investments
Redmile invests primarily in U.S. and non-U.S. healthcare companies.[1](https://hedgefunddb.com/Home/FundDetails/801-67747/REDMILE-GROUP-LLC) The firm runs two kinds of vehicles. The first is a hedge-fund complex of pooled vehicles, including Delaware and Cayman master-feeder structures (fund setup pooling investors via feeder funds into one master fund) and an ERISA fund; Form D records show Redmile Capital Offshore Fund Ltd raised $2,120.8M with $1,344.0M in AUM, and Redmile Strategic Master Fund LP raised $498.6M with $976.3M in AUM.[1](https://hedgefunddb.com/Home/FundDetails/801-67747/REDMILE-GROUP-LLC) • [4](https://aum13f.com/person/jeremy-green) The second is a set of venture-style partnerships, including Redmile Private Investments I/II and Redmile Biopharma Investments I/II/III, whose general partners are Redmile affiliates.[1](https://hedgefunddb.com/Home/FundDetails/801-67747/REDMILE-GROUP-LLC) The biotech partnerships raised $218.3M (Fund I), $675.4M (Fund II), and $500.2M (Fund III, with $1,133.8M in AUM), and the crossover vehicle RedCo II Master Fund LP reported $1,555.9M in AUM.[4](https://aum13f.com/person/jeremy-green) Green is named as an executive officer or promoter on Redmile Form D filings spanning 2011 to 2026.[4](https://aum13f.com/person/jeremy-green)
This structure lets the firm take both public-market positions through the hedge funds and concentrated, board-level stakes in clinical-stage biotechs through the biopharma partnerships, with the same portfolio manager signing the insider filings for both.[5](https://www.secform4.com/insider-trading/1650527.htm)
## Notable investments and exits
The Form 4 (SEC filing disclosing insider trades and holdings) record gives a position-level view of Redmile's winners and losers.
**Augmedix**: in October 2024 Redmile sold 32,086,172 shares at $2.35 for $75,402,504, exiting the position.[5](https://www.secform4.com/insider-trading/1650527.htm) **ADC Therapeutics** saw a partial sale on 31 March 2026 of 5,880,415 shares at $3.3393 for $19,636,340, with 22.9 million shares retained.[5](https://www.secform4.com/insider-trading/1650527.htm) **IGM Biosciences** went the other way: on 14 August 2025 Redmile disposed of 2,964,843 shares at $0, indicating a total loss on the position.[5](https://www.secform4.com/insider-trading/1650527.htm) Green also added to **Fate Therapeutics**, buying 397,964 shares at $1.68 ($668,580) in December 2024, and bought 222,222 [Absci](https://www.edgepedia.org/absci) shares at $4.50 ($999,999) as a director in March 2024.[5](https://www.secform4.com/insider-trading/1650527.htm)
The current public portfolio is concentrated in a handful of names. The 13F holdings show Scholar Rock as the top position at $445,715,088, or 29.51% of the portfolio, after a +74% gain.[2](https://www.insidermonkey.com/hedge-fund/redmile-group/495/) 2026 13G/13D filings include [Shattuck Labs](https://www.edgepedia.org/shattuck-labs) (June/July 2026) and Annexon, Nurix, Neurogene, and Scholar Rock (14 August 2026).[2](https://www.insidermonkey.com/hedge-fund/redmile-group/495/)
## By the numbers
Redmile's Form ADV dated March 2024 reported $6,473,965,022 in discretionary assets across 27 clients, while its Q1 2024 13F showed $2,724,553,242 in 13F securities with a 41.91% top-10 concentration.[2](https://www.insidermonkey.com/hedge-fund/redmile-group/495/) By August 2026 the reported public portfolio was roughly $1.49B.[2](https://www.insidermonkey.com/hedge-fund/redmile-group/495/) Fund-level performance figures for the 2021-2024 biotech downturn are not available in the sources retrieved; the position record (a $75.4M Augmedix exit, a $19.6M ADC sale, and a $0 IGM write-off) is the closest available proxy.[5](https://www.secform4.com/insider-trading/1650527.htm)
## Boards and public positions
Green's insider filings identify him as Director and 10% Owner at IGM Biosciences, Fate Therapeutics, Shattuck Labs, and Absci, and as a 10% Owner via RedCo II Master Fund L.P. at [ADC Therapeutics](https://www.edgepedia.org/adc-therapeutics) and Augmedix.[5](https://www.secform4.com/insider-trading/1650527.htm) He is listed as Director on the Form D for 1Life Healthcare Inc (One Medical), matching past board service there.[4](https://aum13f.com/person/jeremy-green)
Outside investing, his Health Innovators Fellowship biography states that he was previously a trustee and non-executive director of the Prince of Wales Foundation, and that he is a Fellow of the fourth class of the Health Innovators Fellowship and a member of the Aspen Global Leadership Network.[6](https://lanterncare.com/members/jeremy-green/) King's Trust USA's board page lists him as board chair of King's Trust USA (formerly Prince's Trust USA), a role he has held since the organization's founding in 2019, and he has been a trustee of The King's Trust Group since 2022.[6](https://lanterncare.com/members/jeremy-green/) • [8](https://kingstrust.us/about-us/) No interviews, op-eds, or recorded public statements by Green on biotech investing or drug development were found in the sources retrieved.
## Recent developments
The documented record from 2024 onward is active on several fronts. In October 2024 Redmile fully exited Augmedix for $75.4M.[5](https://www.secform4.com/insider-trading/1650527.htm) In December 2024 Green bought into Fate Therapeutics at $1.68.[5](https://www.secform4.com/insider-trading/1650527.htm) In August 2025 the IGM Biosciences position was written off at $0.[5](https://www.secform4.com/insider-trading/1650527.htm) In 2026 the firm restated an insider filing: an amended Form 4 for Fate Therapeutics accepted 23 April 2026 corrected a 22 April filing that had misstated the reference price of cash-settled swap agreements novated by RedCo II Master Fund LP to two wholly-owned subsidiaries; Green signed as Managing Member of RedCo II (GP), LLC, with Redmile entities identified as Director and 10%+ Owner of Fate Therapeutics.[7](https://portfoliosavvy.com/report/000110465926047974-redmile-group-llc-2026-04-20-restatement) The same year brought the ADC Therapeutics partial sale, new 13G/13D filings across five names, and a reported public portfolio of about $1.49B as of August 2026.[5](https://www.secform4.com/insider-trading/1650527.htm) • [2](https://www.insidermonkey.com/hedge-fund/redmile-group/495/)
## References
1. Redmile Group, LLC - Form ADV description, Hedge Fund Database. https://hedgefunddb.com/Home/FundDetails/801-67747/REDMILE-GROUP-LLC
2. Jeremy Green - Redmile Group - 2026 13F Holdings, Performance, and AUM, Insider Monkey. https://www.insidermonkey.com/hedge-fund/redmile-group/495/
3. Jeremy Charles Green - Managing Member at Redmile Group, LLC, PrivateFundData. https://privatefunddata.com/fund-employees/jeremy-charles-green-2810548/
4. Jeremy Green | AUM 13F (Form D and role index). https://aum13f.com/person/jeremy-green
5. Green Jeremy - Insider Trades & Share Buys/Sales, SECForm4. https://www.secform4.com/insider-trading/1650527.htm
6. Jeremy Green - Lantern (Health Innovators Fellowship bio). https://lanterncare.com/members/jeremy-green/
7. Redmile Group, LLC 2026-04-20 Form 4/A - Fate Therapeutics (FATE), PortfolioSavvy. https://portfoliosavvy.com/report/000110465926047974-redmile-group-llc-2026-04-20-restatement
8. About us (kingstrust.us). https://kingstrust.us/about-us/
---
*Topic: Encyclopedia › Society and history › Economics and business › Founders, operators, and investors › Venture and growth investors › Life-science venture and company creation › Biotech venture capital partners › Titles A to J*
*Initially written Sep 17, 2026 · Reviewed: Sep 30, 2026 · Edited: Sep 30, 2026; Oct 11, 2026; Oct 15, 2026 · Last review: Sep 30, 2026*
*Copyright 2026 EdgeChat AI, a subsidiary of Biostate AI.*
License: Edgepedia Community License 1.0, https://www.edgepedia.org/edgepedia/license